To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Do you support it?
Want to know if it passes?
We'll email you when HR 741 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 741.
You're tracking HR 741
We'll email you the moment it moves.
HR 741 — To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Last action — Referred to the Subcommittee on Health.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 112th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.
Bill Text
We don't have the full text on file for this bill yet.
Read HR 741 on the official United States source →Action History
-
Referred to the Subcommittee on Health.
-
Referred to the House Committee on Energy and Commerce.
Sponsors
- Jo Emerson · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 741 do?
- Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.
- Who sponsors HR 741?
- HR 741 is sponsored by Jo Emerson (R).
- What is the current status of HR 741?
- This bill died with 112th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 741?
- Track HR 741 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 741
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 741
Last checked for changes about 10 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →